| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 1/2 | |||
| NCT05849480 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin… | Biliary Cancer | Recruiting |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Solid Tumor, Adult | Active, Not Recruiting |
| Phase 1 | |||
| NCT05929235 | A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced… | Advanced Urothelial Carcinoma | Recruiting |
| NCT07475572 | A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With… | Melanoma | Not Yet Recruiting |
| NCT01822652 | 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch… | Neuroblastoma | Active, Not Recruiting |
| NCT04526691 | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without… | Advanced or Metastatic NSCLC | Active, Not Recruiting |
| NCT07388550 | Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of… | Post-Acute COVID-19 Syndrome | Not Yet Recruiting |